BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 26986147)

  • 1. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
    Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
    Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
    Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
    Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed examination of HLA antibody development on renal allograft failure and function.
    Zhu L; Lee PC; Everly MJ; Terasaki PI
    Clin Transpl; 2008; ():171-87. PubMed ID: 19711514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
    Romphruk AV; Simtong P; Suntornnipat J; Sudwilai Y; Cheunta S; Chan-On C; Leelayuwat C
    Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
    Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
    Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
    Lobo LJ; Aris RM; Schmitz J; Neuringer IP
    J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft Immunocomplex Capture Fluorescence Analysis to Detect Donor-Specific Antibodies and HLA Antigen Complexes in the Allograft.
    Nakamura T; Ushigome H; Watabe K; Imanishi Y; Masuda K; Matsuyama T; Harada S; Koshino K; Iida T; Nobori S; Yoshimura N
    Immunol Invest; 2017 Apr; 46(3):295-304. PubMed ID: 28151033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection.
    Malard-Castagnet S; Dugast E; Degauque N; Pallier A; Soulillou JP; Cesbron A; Giral M; Harb J; Brouard S
    Hum Immunol; 2016 Nov; 77(11):1076-1083. PubMed ID: 26546874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
    Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.